Clinical Trials Logo

Healthy Subjects clinical trials

View clinical trials related to Healthy Subjects.

Filter by:

NCT ID: NCT03463343 Completed - Healthy Subjects Clinical Trials

Neurophysiologic Effects of Cervical Spinal Manipulation in Asymptomatic Individuals

Start date: May 1, 2013
Phase: N/A
Study type: Interventional

This study had the goal of analyse the neurophysiologic effects of both mechanical and manual cervical manipulation, in asymptomatic individuals.

NCT ID: NCT03463044 Completed - Healthy Subjects Clinical Trials

Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

Start date: April 1, 2016
Phase: Phase 1
Study type: Interventional

This was a single center, randomized, placebo-controlled study with a sequential i.v. dose escalation cohorts design, to assess safety, tolerability and pharmacokinetics of MOTREM (nangibotide) in healthy volunteers

NCT ID: NCT03451110 Completed - Healthy Subjects Clinical Trials

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

Start date: February 5, 2018
Phase: Phase 1
Study type: Interventional

This study will be conducted to evaluate the effect of lemborexant 10 milligrams (mg) (at steady state) on the pharmacokinetics (PK) of a single-dose combined oral contraceptive, Loestrin 1.5/30 (containing 0.030 mg of ethinyl estradiol and 1.5 mg of norethindrone), and to evaluate the effect of fluconazole 200 mg (at steady state) and a single dose of famotidine 40 mg (an H2 blocker) on the PK of a single oral dose of lemborexant 10 mg.

NCT ID: NCT03443960 Completed - Healthy Subjects Clinical Trials

Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules

Start date: January 29, 2018
Phase: Phase 1
Study type: Interventional

This will be a single center, comparative pharmacokinetic, open-label, randomized, multiple-dose, 1-period, 2-arm, parallel study of TNX-102 SL 5.6 mg (administered as 2 x 2.8 mg tablets) to AMRIX® (cyclobenzaprine hydrochloride [HCl] extended-release [ER] capsules), 30 mg.

NCT ID: NCT03436849 Completed - Healthy Subjects Clinical Trials

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects

Start date: February 22, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of single and multiple oral doses of ESN364 in healthy Japanese male and pre- and post-menopausal female subjects. This study will also evaluate the pharmacokinetics (PK) of ESN364 and its metabolite, and the pharmacodynamics (PD) of ESN364 after single and multiple oral doses administration in healthy Japanese male and pre- and post-menopausal female subjects.

NCT ID: NCT03431233 Completed - Healthy Subjects Clinical Trials

Effect of Premeal Protein-bar on Food Intake

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

The aim of this study is to explore premeal protein-enriched bar effect in food intake in healthy subjects.

NCT ID: NCT03424564 Completed - Healthy Subjects Clinical Trials

Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects

Start date: March 20, 2018
Phase: Phase 1
Study type: Interventional

This study will be conducted to evaluate the pharmacokinetics of perampanel following single and multiple oral doses in Chinese healthy male and female participants.

NCT ID: NCT03414723 Completed - Diabetes Mellitus Clinical Trials

A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

Start date: January 15, 2018
Phase: Phase 1
Study type: Interventional

Primary Objective: To evaluate the effects of multiple-dose ramipril on the steady state pharmacokinetic (PK) parameters of sotagliflozin and its main metabolite (sotagliflozin-3-O-glucuronide) in healthy male and female subjects. Secondary Objectives: - To assess the effects of multiple-dose sotagliflozin on the PK of ramipril and its active metabolite (ramiprilat). - To assess the safety and tolerability of multiple-dose sotagliflozin with and without multiple-dose of ramipril.

NCT ID: NCT03400241 Completed - Healthy Subjects Clinical Trials

Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler

Start date: February 19, 2018
Phase: Phase 1
Study type: Interventional

Absorption of inhaled tiotropium is compared between three Tiotropium Easyhaler products and Spiriva capsules inhaled via HandiHaler. All subjects will receive all products as a single dose.

NCT ID: NCT03389321 Completed - Healthy Subjects Clinical Trials

Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics

Start date: January 9, 2018
Phase: Phase 1
Study type: Interventional

Both macitentan and riociguat are indicated in the treatment of pulmonary arterial hypertension (PAH) and may be administered concomitantly. The primary objective of this study is to evaluate the effect of macitentan administered for 11 days on the pharmacokinetics (PK) (i.e., amount and time of presence in the blood of riociguat) of a single dose of riociguat in healthy male subjects.